PDCD1 and melanoma: Analyses of ICI treatment beyond progression of anti-PD-1/PD-L1 in metastatic urothelial carcinoma, renal cell carcinoma, melanoma, and metastatic NSCLC have been reported (18, 19, 29, 30).